Evidence map›Paper›PMID 36907428›Full record

ArticleMatrix biology : journal of the International Society for Matrix Biology2023

Conditional expression of endorepellin in the tumor vasculature attenuates breast cancer growth, angiogenesis and hyaluronan deposition.

Carolyn G Chen, Aastha Kapoor, Christopher Xie, Alison Moss, Rajanikanth Vadigepalli, Sylvie Ricard-Blum, Renato V Iozzo

Open access · greenAbstract read
In one paragraph

Article in Matrix biology : journal of the International Society for Matrix Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Carolyn G ChenDepartment of Pathology and Genomic Medicine and the Translational Cellular Oncology Program, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA.
Aastha KapoorDepartment of Pathology and Genomic Medicine and the Translational Cellular Oncology Program, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA.
Christopher XieDepartment of Pathology and Genomic Medicine and the Translational Cellular Oncology Program, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA.
Alison MossDepartment of Pathology and Genomic Medicine and the Translational Cellular Oncology Program, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA.
Rajanikanth VadigepalliDepartment of Pathology and Genomic Medicine and the Translational Cellular Oncology Program, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA.
Sylvie Ricard-BlumInstitute of Molecular and Supramolecular Chemistry and Biochemistry, University Claude Bernard Lyon 1, Villeurbanne, France.
Renato V IozzoDepartment of Pathology and Genomic Medicine and the Translational Cellular Oncology Program, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA. Electronic address: renato.iozzo@jefferson.edu.
Thomas Jefferson University · USUniversité Claude Bernard Lyon 1 · FR

Funding

NEOPLASTIC MODULATION OF PROTEOGLYCAN METABOLISMR01CA039481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI IOZZO, RENATO V. · 1985 to 2020
$7.1M
Training in Tissue Engineering and Regenerative MedicineT32AR052273 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI SHAPIRO, IRVING M · 2006 to 2020
$3.3M
Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagyR01CA245311 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 2020 to 2024
$2.0M
NCI NIH HHS R01 CA039481NCI NIH HHS R01 CA245311NIAMS NIH HHS T32 AR052273
6 · The paper itself

Abstract

The tumor stroma of most solid malignancies is characterized by a pathological accumulation of pro-angiogenic and pro-tumorigenic hyaluronan driving tumorigenesis and metastatic potential. Of all three hyaluronan synthase isoforms, HAS2 is the primary enzyme that promotes the build-up of tumorigenic HA in breast cancer. Previously, we discovered that endorepellin, the angiostatic C-terminal fragment of perlecan, evokes a catabolic mechanism targeting endothelial HAS2 and hyaluronan via autophagic induction. To explore the translational implications of endorepellin in breast cancer, we created a double transgenic, inducible Tie2Cre

Indexed as

Hyaluronic AcidNeoplasmsAnimalsAutophagyHeparan Sulfate ProteoglycansHyaluronan SynthasesMiceNeovascularization, PathologicPeptide FragmentsTumor Microenvironmentendorepellin protein, mouseHeparan Sulfate ProteoglycansHyaluronan SynthasesHyaluronic AcidPeptide FragmentsATG5AutophagyCancer growthHyaluronan synthaseProteoglycans

Identifiers

PMID36907428
PMCPMC10259220
OpenAlexW4323928847

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.